FoPE Raises Concerns Over New Schedule M’s Impact On Cosmetic Manufacturing

New Delhi: The pharmaceutical industry has raised concerns regarding the government’s newly notified schedule M that proposes a blanket ban on manufacture of any other article or product apart from drugs in the units licensed for drug production.

The Federation of Pharma Enterprises (FoPE) that represents medium and small-scale enterprises has written to the health ministry citing that setting up a new plant exclusively for cosmetic manufacturing is financially not viable. It sought that such units be permitted to manufacture cosmetics in the area dedicated for making topical products such as external preparations such as creams and lotions.

According to FoPE’s representation, the requirement as specified in the revised Schedule M has caused difficulties to members which are medium scale and small-scale pharmaceutical entrepreneurs having well-equipped facilities with good manufacturing practices.

An exception was provided from the requirement that no manufacturing activity shall be undertaken therein except in respect of units licensed prior to 2001. In view of the aforesaid exception, units licensed prior to 2001 were allowed to manufacture allied items such as nutraceuticals and ayurvedic medicines in the same plant. They were also allowed to manufacture cosmetic products in the section meant for topical products i.e. external preparations.

“However, some of them licensed prior to 2011 are engaged in the manufacture of cosmetics in the external products section. Now, in view of revised Schedule M, they will have to set up a new plant exclusively for cosmetic manufacturing which is financially not viable,” it said.

They also noted that entrepreneurs from 1988 till 2024 had no difficulties or issues about quality for either drug or cosmetics products as necessary precautions including line clearance and preventing cross contamination were taken by the concerned licensees.

Against this background, FoPE has urged the government to allow the medium scale and small-scale manufacturers to make cosmetic products in the section designated for manufacturing of topical product i.e. external preparations such as creams and ointments.

FoPE has asked the government to consider their request as cosmetic products are mostly in the form of creams, suspensions, lotions that are like topical products such as creams, and ointments. It also said that like topical products, cosmetic products are also used externally, mostly for aesthetic purposes.

“Thus, there is a strong logical justification for allowing cosmetic products in Section dedicated for manufacture of external preparation as by allowing it the cosmetic will be manufactured in much more stringent good manufacturing practices requirement as compared to those specified in Seventh Schedule of the Cosmetics Rules, 2020,” the letter to the health secretary said.

Related Posts

Four booked for cheating pharma firm manager of ₹26 lakh with promise of PDO job

A job racket promising appointments as Panchayat Development Officers (PDOs) in the Rural Development and Panchayat Raj Department has come to light after a senior manager of a private pharmaceutical…

Puducherry drugs inspector suspended after counterfeit medicine crackdown

An order issued by Secretary to Government (Health) Choudhary Mohammed Yasin on July 23 stated that Anandakirouchenane, as Drugs Controller, was unable to stop the illegal manufacture of drugs, despite…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Four booked for cheating pharma firm manager of ₹26 lakh with promise of PDO job

Four booked for cheating pharma firm manager of ₹26 lakh with promise of PDO job

Puducherry drugs inspector suspended after counterfeit medicine crackdown

Puducherry drugs inspector suspended after counterfeit medicine crackdown

Researchers discover a compound that can boost ageing muscle repair

Researchers discover a compound that can boost ageing muscle repair

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit